We identified rare coding variants associated with Alzheimer's disease in a three-stage case-control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a wholeexome microarray. In stage 2, we tested associated variants (P < 1 × 10 −4 ) in 35,962 independent samples using de novo genotyping and imputed genotypes. In stage 3, we used an additional 14,997 samples to test the most significant stage 2 associations (P < 5 × 10 −8 ) using imputed genotypes. We observed three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease: a protective variant in PLCG2 (rs72824905: p.Pro522Arg, P = 5.38 × 10 −10 , odds ratio (OR) = 0.68, minor allele frequency (MAF) cases = 0.0059, MAF controls = 0.0093), a risk variant in ABI3 (rs616338: p.Ser209Phe, P = 4.56 × 10 −10 , OR = 1.43, MAF cases = 0.011, MAF controls = 0.008), and a new genome-wide significant variant in TREM2 (rs143332484: p.Arg62His, P = 1.55 × 10 −14 , OR = 1.67, MAF cases = 0.0143, MAF controls = 0.0089), a known susceptibility gene for Alzheimer's disease. These proteinaltering changes are in genes highly expressed in microglia and highlight an immune-related protein-protein interaction network enriched for previously identified risk genes in Alzheimer's disease. These genetic findings provide additional evidence that the microglia-mediated innate immune response contributes directly to the development of Alzheimer's disease.
Late-onset Alzheimer's disease (LOAD) has a substantial genetic component (h 2 = 58-79%) 1 . Nearly 30 LOAD susceptibility loci [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] are known, and risk is highly polygenic 13 . However, these loci explain only a proportion of disease heritability. Rare variants also contribute to disease risk [14] [15] [16] [17] . Recent sequencing studies identified a number of genes that have rare variants associated with Alzheimer's disease [9] [10] [11] [18] [19] [20] [21] [22] [23] [24] . Our approach to rare variant discovery is to genotype a large sample with microarrays targeting known exome variants with follow-up using genotyping and imputed genotypes in a large independent sample. This is a cost-effective alternative to de novo sequencing [25] [26] [27] [28] [29] .
We applied a three-stage design ( Supplementary Fig. 1 ) using subjects from the International Genomics of Alzheimer's Project (IGAP) ( Table 1 and Supplementary Tables 1 and 2) . In stage 1, we genotyped 16,097 LOAD cases and 18,077 cognitively normal elderly controls using the Illumina HumanExome microarray. Data from multiple consortia were combined in a single-variant meta-analysis (Online Methods) assuming an additive model. In total, 241,551 variants passed quality control (Supplementary Table 3 ). Of these, 203,902 were polymorphic, 26,947 were common (MAF ≥ 5%), and 176,955 were low frequency or rare (MAF < 5%). We analyzed common variants using a logistic regression model in each sample cohort and combined data using METAL 30 . Rare and low-frequency variants were analyzed using the score test and data were combined with SeqMeta 31 (Supplementary Fig. 2 ).
We reviewed cluster plots for variants showing association (P < 1 × 10 −4 ) and identified 43 candidate variants (Supplementary Table 4) , excluding known risk loci (Supplementary Table 5 ). In stage 2, we tested these for association in 14,041 LOAD cases and 21,921 controls, using genotypes derived from de novo genotyping and imputation (Online Methods). We carried forward single-nucleotide variants (SNVs) with genome-wide significant associations and consistent directions of effect to stage 3 where genotypes for 6,652 independent cases and 8,345 controls were imputed using the Haplotype Reference Consortium resource 32, 33 (Online Methods and Supplementary Table 6) . We identified four rare coding variants with genome-wide significant association signals with LOAD (P < 5 × 10 −8 ) ( Table 2 and Supplementary  Tables 7 and 8 ). The first is a missense variant p.Pro522Arg (P = 5.38 × 10 −10 , OR = 0.68) in PLCG2 (phospholipase C γ2) (Fig. 1a, Table 2 , Supplementary Fig. 3 , and Supplementary Table 9 ). This variant is associated with decreased risk of LOAD, showing a MAF of 0.0059 in cases and 0.0093 in controls. The reference allele (Pro522) is conserved across several species (Supplementary Fig. 4) . Gene-wide analysis showed nominal evidence for association at P = 1.52 × 10 −4 (Supplementary Tables 10 and 11), and we found no other independent association at this gene (Supplementary Fig. 5 ).
The second new association is a missense change p.Ser209Phe (P = 4.56 × 10 −10 , OR = 1.43) in ABI3 (B3-domain-containing transcription factor ABI3). The Phe209 allele showed consistent evidence for increasing LOAD risk across all stages, with a MAF of 0.011 in cases and 0.008 in controls (Fig. 1b, Table 2 , Supplementary Fig. 6 , and Supplementary Table 12 ). The reference allele is conserved across multiple species (Supplementary Fig. 7) . Gene-wide analysis showed nominal evidence of association (P = 5.22 × 10 −5 ) (Supplementary 1 3 7 4 VOLUME 49 | NUMBER 9 | SEPTEMBER 2017 Nature GeNetics l e t t e r s Tables 10 and 11 ). The B4GALNT2 gene, adjacent to ABI3, contained an independent suggestive association ( Supplementary Fig. 8 ), but this failed to replicate in subsequent stages (P combined = 1.68 × 10 −4 ) (Supplementary Table 7) .
Following reports of suggestive association with LOAD 34, 35 , we report the first evidence for genome-wide significant association at TREM2 coding variant p.Arg62His (P = 1.55 × 10 −14 , OR = 1.67), with a MAF of 0.0143 in cases and 0.0089 in controls (Fig. 1c, Table 2 , Supplementary Figs. 9 and 10, and Supplementary Table 13) . We also observed evidence of association for the previously reported 9, 11 TREM2 rare variant p.Arg47His ( Table 2) . These variants are not in linkage disequilibrium (Supplementary Table 14) , and conditional analyses confirmed that p.Arg62His and p.Arg47His are independent risk variants (Supplementary Fig. 11 ). Gene-wide analysis of TREM2 showed a genome-wide significant association (P SKAT = 1.42 × 10 −15 ) (Supplementary Tables 10 and 11) . Removal of p.Arg47His and the p.Arg62His variants from the analysis diminished the genewide association, but the signal remained interesting (P SKAT-O = 6.3 × 10 −3 , P Burden = 4.1 × 10 −3 ). No single SNV was responsible for the remaining gene-wide association ( Supplementary Fig. 11 and Supplementary Table 13), suggesting that there are additional risk variants in TREM2. We previously reported a common variant association with LOAD near TREM2, in a genome-wide association study (GWAS) of cerebrospinal fluid tau and phosphorylated tau (P-tau) 36 . We also observed a different suggestive common variant signal in another LOAD case-control study (P = 6.3 × 10 −7 ) 2 .
We previously identified eight gene pathway clusters significantly enriched in common variants associated with Alzheimer's disease 36 . To test whether biological enrichments observed in common variants are also present in rare variants, we used the rare variant data (MAF < 1%) to reanalyze these eight Alzheimer's disease-associated pathway clusters (Online Methods and Supplementary Table 15) . We used Fisher's method to combine gene-wide P values for all genes in each cluster. After correction for multiple testing, we observed enrichment for immune response (P = 8.64 × 10 −3 ), cholesterol transport (P = 3.84 × 10 −5 ), hemostasis (P = 2.10 × 10 −3 ), clathrin-AP2 adaptor complex (P = 9.20 × 10 −4 ), and protein folding (P = 0.02). We also performed pathway analyses on the rare variant data presented here using all 9,816 pathways used previously. The top pathways are related to lipoprotein particles, cholesterol efflux, B cell differentiation and immune response, areas of biology also enriched when common variants are analyzed 37 (Supplementary Table 16 ). 
l e t t e r s
Previous analysis of normal brain coexpression networks identified four gene modules that are enriched for common variants associated with LOAD risk 2, 3711 . These four modules are enriched for immune-response genes. We identified 151 genes present in two or more of these four modules, and these showed a strong enrichment for LOAD-associated common variants (P = 4.0 × 10 −6 ) 36 and for rare variants described here (MAF < 1%) (P = 1.17 × 10 −6 ; Supplementary Table 15) . We then used a set of high-quality proteinprotein interactions 37 to construct, from these 151 genes, an interaction network containing 56 genes, including PLCG2, ABI3, and TREM2 ( Fig. 2 and Online Methods). This subset is strongly enriched for association signals from both the previous common variant analysis (P = 5.0 × 10 −6 ; Supplementary Fig. 12 ) 38 . Other known LOADassociated loci with the same expression pattern included SORL1, the MS4A gene cluster, and HLA-DRB1. PLCG2, ABI3, and TREM2 are upregulated in LOAD human cortex and in two amyloid precursor protein (APP) mouse models. However, when corrected for levels of other microglial genes, these changes in expression appeared to be related to microgliosis (Supplementary Tables 19 and 20) .
PLCG2 ( Supplementary Fig. 13 ) encodes a transmembrane signaling enzyme (PLCγ2) that hydrolyzes the membrane phospholipid PIP 2 (1-phosphatidyl-1d-myoinositol 4,5-bisphosphate) to secondary messengers IP 3 (myoinositol 1,4,5-trisphosphate) and DAG (diacylglycerol). IP 3 is released into the cytosol and acts at the endoplasmic reticulum where it binds to ligand-gated ion channels to increase cytoplasmic Ca 2+ . DAG remains bound to the plasma membrane where it activates two major signaling molecules, protein kinase C (PKC) and Ras guanyl-nucleotide-releasing proteins (RasGRPs), which initiate the NF-κB and mitogen-activated protein kinase (MAPK) pathways. While the IP 3 -DAG-Ca 2+ signaling pathway is active in many cells and tissues, in brain PLCG2 is primarily expressed in microglial cells. PLCG2 variants also cause antibody deficiency and immune dysregulation (PLAID) and autoinflammation and PLAID (APLAID) 39 . Genomic deletions (PLAID) and missense mutations (APLAID) affect the cSH2 autoinhibitory regulatory region. The result is a complex mix of loss and gain of function in cellular signaling 39 .
Functional annotation ( Supplementary Table 21 ) suggests that ABI3 (Supplementary Fig. 14) has a role in the innate immune response via interferon-mediated signaling 40 . ABI3 is coexpressed with INPP5D (P = 2.2 × 10 −10 ), a gene previously implicated in LOAD risk 2 . ABI3 has an important role in actin cytoskeleton organization through participation in the WAVE2 complex 41 , a complex that regulates multiple pathways leading to T cell activation 42 . l e t t e r s TREM2 encodes a transmembrane receptor present in the plasma membrane of brain microglia (Supplementary Fig. 15 ). TREM2 protein forms an immune-receptor-signaling complex with DAP12. Receptor activation results in activation of Syk and ZAP70 signaling, which in turn activates PI3K activity and influences PLCγ2 activity 43 . In microglia, TREM2-DAP12 induces M2-like activation 44 and participates in recognition of membrane debris and amyloid deposits, resulting in microglial activation and proliferation [45] [46] [47] . When Trem2-homozygous-knockout or Trem2-heterozygous-knockout mice are crossed with APP transgenics that develop plaques, the size and number of microglia associated with plaques are markedly reduced 46, 47 .TREM2 risk variants are located within exon 2, which is predicted to encode the conserved ligand-binding extracellular region of the protein. Any disruption in this region may attenuate or abolish TREM2 signaling, resulting in loss or decrease in TREM2 function 47 .
The 56-gene interaction network identified here is enriched in immune-response genes and includes TREM2, PLCG2, ABI3, SPI1, l e t t e r s INPP5D, CSF1R, SYK, and TYROBP (Fig. 2) . SPI1 is a central transcription factor in microglial activation state that has a significant gene-wide association with Alzheimer's disease 5 and is in the proximity of genome-wide significant signals identified by IGAP 2 . Loss-of-function mutations in CSF1R cause hereditary diffuse leukoencephalopathy with spheroids, a white matter disease related to microglial dysfunction 48 . Activated microglial cells surround plaques 49, 50 , a finding consistently observed in Alzheimer's disease brain in humans and transgenic mouse models of Alzheimer's disease 51 . In the brains of mouse models of Alzheimer's disease, synaptic pruning associates with activated microglial signaling 52 . Pharmacological targeting of CSF1R inhibits microglial proliferation and shifts the microglial inflammatory profile to an anti-inflammatory phenotype in mouse models 53 . SYK regulates amyloid-β production and tau hyperphosphorylation 54 , is affected by the INPP5D-CD2AP complex 55 encoded by two LOADassociated genes 2 , and mediates phosphorylation of PLCγ2 (ref. 56) . Notably, the antihypertensive drug nilvadipine, currently in a phase 3 Alzheimer's disease clinical trial, targets SYK as well as TYROBP, a hub gene in an Alzheimer's disease-related brain expression network 38 that encodes the TREM2 complex protein DAP12. We identified three rare coding variants in PLCG2, ABI3, and TREM2 with genome-wide significant associations with LOAD that are part of a common innate immune response. This work provides additional evidence that the microglial response in LOAD is directly part of a causal pathway leading to disease and is not simply a downstream consequence of neurodegeneration 46, 47, 57, 58 . Our network analysis supports this conclusion. In addition, PLCγ2, as an enzyme, represents the first classically druggable target, to our knowledge, to emerge from LOAD genetic studies. The variants described here account for a small portion of the 'missing heritability' of Alzheimer's disease. The remaining heritability may be due to a large number of common variants of small effect. For rare variants, there may be additional exonic sites with lower MAF or effect size, and/or intronic and intergenic sites. Complete resolution of the heritability for Alzheimer's disease will be facilitated by larger sample sizes and more comprehensive sequence data.
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In the GERAD/PERADES consortium, 1,740 participants (888 LOAD cases and 852 controls) did not have age information available and were excluded from the adjusted analyses. Therefore, 16,160 cases and 17,967 controls were included in the unadjusted analyses, and 15,272 cases and 17,115 controls were included in the adjusted analyses. The primary analysis used the unadjusted model given the larger sample size this provided. See Supplementary Figure  2 for quantile-quantile plots of unadjusted and adjusted analyses.
Stage 2. We tested association with LOAD using the score test and seqMeta package. Analyses were conducted under the two models described above, in the analysis groups indicated in Supplementary Table 2 . Analyses were undertaken globally in the GERAD/PERADES cohort and by country in the IGAP cohorts, with the EADI1 cohort only including French participants and the ACE cohort including only Spanish participants. Following the format of the IGAP mega meta-analysis 2 , four principal components were included for the EADI1 data set and one was included in the Italian and Swedish IGAP clusters. Meta-analysis was undertaken in the SeqMeta R package.
Stage 3. The association analyses performed followed stage 1 and stage 2 analytical procedures described below, and only variants in ABI3, PLCG2, and TREM2 were examined. For gene-based testing, 10 variants in ABI3, 35 variants in PLCG2, and 13 variants in TREM2 were examined.
Pathway and gene set enrichment analysis. The eight biological pathway clusters previously identified as enriched for association in the IGAP data set 37 were tested for enrichment in this rare variation study (Supplementary Table  15 ) to test whether the biological enrichments observed in common variants also apply to rare variants. Genes were defined without surrounding genomic sequence, as this yielded the most significant excess of enriched pathways in the common variation data set 37 . Gene-wide SKAT-O P values for the variants of interest were combined using Fisher's combined probability test. Given the low degree of LD 65 between rare variants, our primary analyses did not control for LD between pathway genes. However, as a secondary analysis, the APOE region was removed and, for each pair of pathway genes within 1 Mb of each other, the gene with the more significant SKAT-O P value was removed. This highly conservative procedure removes any potential bias in the enrichment test both from LD between the genes and dropping less significant genes from the analysis.
We also performed pathway analyses on the rare variant data presented using all 9,816 pathways used previously. The top pathways are related to lipoprotein particles, cholesterol efflux, B cell differentiation, and immune response, and they closely parallel the common variant results (Supplementary Table 16 ).
Protein interaction analysis. Previous analysis of normal brain co-expression networks identified four gene modules that were enriched for common variants associated with Alzheimer's disease risk in the IGAP GWAS. Each of these four modules was also found to be enriched for immune-related genes. The 151 genes present in two or more of these four modules were particularly strongly enriched for IGAP GWAS association. This set of 151 co-expressed genes thus contains genes of relevance to Alzheimer's disease etiology. To identify these genes and clarify biological relationships between them for future study, protein interaction analysis was performed. First, a list of high-confidence (confidence score > 0.7) human protein-protein interactions was downloaded from the latest version (v10) of the STRING database (http://string-db.org/). Then, protein interaction networks were generated as follows:
1. Choose a gene to start the network (the 'seed' gene). 2. For each remaining gene in the set of 151 genes, add it to the network if its corresponding protein shows a high-confidence protein interaction with a protein corresponding to any gene already in the network. 3. Repeat step 2 until no more genes can be added. 4. Note the number of genes in the network. 5. Repeat, choosing each of the 151 genes in turn as the seed gene.
The largest protein interaction network resulting from this procedure resulted in a network of 56 genes connected by high-confidence protein interactions. To test whether this network was larger than expected by chance, given the total number of protein-protein interactions for each gene, random sets of 151 genes were generated, with each gene chosen to have the same total number of protein-protein interactions as the corresponding gene in the actual data. Protein networks were generated for each gene as described above, and the size of the largest such network was compared to the observed 56-gene network. 1,000 random gene sets were generated, and none of them yielded a protein interaction network as large as 56 genes. Note that the procedure for generating the protein interaction network relies only on protein interaction data and is agnostic to the strength of GWAS or rare variant associations for each gene. Thus, the strength of genetic association in the set of 56 network genes can be tested relative to that in the original set of 151 genes without bias.
Gene set enrichment analysis of the protein network. The set of 56 network genes was tested for association enrichment in the IGAP GWAS using ALIGATOR 66 , as was done in the original pathway analysis, using a range of P-value thresholds for defining significant SNPs (and thus the genes containing those SNPs). The same analysis was also performed on the 95 genes in the module overlap but not the protein interaction network (Supplementary Table 17 ). It can be seen that the 56 network genes account for most of the enrichment signal observed in the set of 151 module overlap genes.
The set of 56 network genes, the set of 151 module overlap genes, and the set of 95 genes in the module overlap but not the network were tested for enrichment of association signal in variants with MAF <1% using the gene set enrichment method described above. Both the set of 151 genes (P = 1.17 × 10 −6 ) and the subset of 56 genes (P = 1.08 × 10 −7 ) show highly significant enrichment for association in the rare variants with MAF <1%. It can be seen that the 56 network genes account for most of the enrichment signal observed in the set of 151 module overlap genes (Supplementary Table 17) . Again, the subset of 56 genes accounts for most of the enrichment signal observed in the set of 151 genes, as the remaining 95 genes have only nominally significant enrichment (P = 0.043). Both the set of 151 genes (P = 5.15 × 10 −5 ) and the subset of 56 genes (P = 2.98 × 10 −7 ) show significant enrichment under a conservative analysis excluding the APOE region and correcting for possible LD between the genes (Supplementary Table 17) . Thus, the rare variants show convincing replication of the biological signal observed in the common variant GWAS, and, furthermore, the protein network analysis has refined this signal to a set of 56 interacting genes. Given that TREM2 has a highly significant gene-wide P value (P = 1.01 × 10 −13 ) among variants with MAF <1%, enrichment analyses were run omitting it. Both the set of 151 genes (P = 2.78 × 10 −3 ) and the subset of 56 genes (P = 0.010) (Supplementary Table 18 ) still showed significant enrichment of signal, suggesting that the contribution of rare variants to disease susceptibility in these networks is not restricted to TREM2. Biological follow-up of genetic results is labor intensive and expensive. It is therefore important to concentrate such work on the genes that are most important to Alzheimer's disease susceptibility. Thus, the rationale for reducing the gene set is that it defines a network of genes that are not only related through co-expression and protein interaction, but also show enrichment for genetic association signal. These genes are therefore strong candidates for future biological study.
Gene expression. We examined mRNA expression of the newly associated genes PLCG2 and ABI3 in post-mortem brain tissue from neuropathologically characterized individuals (508 persons): these genes are expressed at low levels in the dorsolateral prefrontal cortex of subjects from two studies of aging with prospective autopsy (ranked 12,965 out of 13,484 expressed genes) 67 . However, ABI3 and PLCG2 were more highly expressed in purified microglia/ macrophages from the cortex of 11 subjects from these cohorts (ranked 1,740 and 2,600, respectively, out of the 11,500 expressed genes) (P.L.D.J., D.A.B. and C.C.W., unpublished data). These findings are consistent with the high levels of expression of both PLCG2 and ABI3 in peripheral monocytes, spleen, and whole blood reported by the ROADmap project and in microglia as reported by Zhang et al. 38 . From the same brain tissue, we examined methylation (n = 714) 68 and H3K9ac acetylation (n = 676) data and found differential methylation at four CpG sites and lower acetylation at two H3K9ac sites adjacent to PLCG2 and ABI3 in relation to increased global neuritic plaque and tangle burden (false discovery rate (FDR) < 0.05). Similarly, high TREM2 expression has been shown to correlate with increasing neuritic plaque burden 69 .
AMP-AD gene expression data. RNA sequencing was used to measure gene expression levels in the temporal cortex of 80 subjects with pathologically
